FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation
- 26 September 2005
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 36 (11) , 977-983
- https://doi.org/10.1038/sj.bmt.1705169
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotypeLeukemia Research, 2004
- Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group UlmBlood, 2002
- Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapyLeukemia, 2002
- Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16)The Hematology Journal, 2002
- Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignanciesBlood, 2001
- Clinical importance of cytogenetics in acute myeloid leukaemiaBest Practice & Research Clinical Haematology, 2001
- Autologous peripheral blood stem cell transplantation for acute myelogenous leukemiaBone Marrow Transplantation, 1997
- Intensive Postremission Chemotherapy in Adults with Acute Myeloid LeukemiaNew England Journal of Medicine, 1994
- Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO)British Journal of Haematology, 1991
- Proposed Revised Criteria for the Classification of Acute Myeloid LeukemiaAnnals of Internal Medicine, 1985